TECH CENTER 1800/2800

10333 RICHMOND, STE. 1100, HOUSTON, TEXAS 77042 (713) 934-7000 FAX: (713) 934-7011

Danny L. Williams
Terry D. Morgan
J. Mike Amerson
Kenneth D. Goodman
Jeffrey A. Pyle
Jaison C. John
Ruben S. Bains

Scott F. Diring*
George J. Oehling*
Shelley P.M. Fussey, Ph.D.*
Mark D. Moore, Ph.D.*
Raymund F. Eich, Ph.D.*
Daren C. Davis*
Stephanie A. Wardwell, Ph.D.*
Mark W. Sincell, Ph.D.*

*Patent Agent

WRITER'S DIRECT DIAL: (713) 934-4079

December 9, 2002

File: 4001.002282

CERTIFICATE OF MAILING 37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date below:

December 9, 2002

Date

Shelley P.M. Fussey

Assistant Commissioner for Patents Washington, DC 20231

RE:

U.S. Application Serial No. 09/351,862; Entitled "Cancer Treatment Kits Using Antibodies to Aminophospholipids"; by Thorpe and Ran; Client Reference: UTSD:549--1

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, PTO Form 1449 and copies of References C67-C70.

No fees are believed to be due in connection with the filing of these materials, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason, the Assistant Commissioner is hereby authorized to deduct said fees from Williams, Morgan & Amerson, P.C. Deposit Account No. 50-0786/4001.002282.

WILLIAMS, MORGAN & AMERSON, P.C.

Assistant Commissioner for Patents December 9, 2002 Page 2

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

23720
PATENT TRADEMARK OFFICE

Respectfully submitted,

Shelley P.M. Fussey, Ph.D.

Reg. No. 39,458 Patent Agent

Encls.

ئام ، المسرد



CERTIFICATE OF MAILING 37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date below:

December 9, 2002

Date

Shelley P.M. Fussey

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Philip E. Thorpe and Sophia Ran

Serial No.: 09/351,862

Filed: July 12, 1999

For: CANCER TREATMENT KITS USING

ANTIBODIES TO

AMINOPHOSPHOLIPIDS

Group Art Unit: 1617

Examiner: Sharareh, S.

Atty. Dkt. No.: 4001.002282

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record in the present case. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A Final Official Action has been received in the present application. However, this Supplemental Information Disclosure Statement is being submitted in an abundance of caution

and should be enterable under 37 C.F.R. § 1.97(d) in light of the following information.

In accordance with 37 C.F.R. § 1.97(e)(2), it is hereby certified that the listed documents were each cited in a communication from a foreign patent office in a related foreign application not more than three months prior to the filing of the present statement. Specifically, the listed documents were cited in a communication mailed from the Australian Patent Office in Australian Application No. 54585/99 (Attorney Docket No. 4001.002201) on October 15, 2002, less than

Should any fees under 37 C.F.R. §§ 1.97(d) and 1.17(p) be due, the Examiner should contact the undersigned representative to discuss deduction from Williams, Morgan & Amerson Deposit Account No. 50-0786/4001.002282.

23720
PATENT TRADEMARK OFFICE

three months before the filing of the present statement.

Respectfully submitted,

Shelley P.M. Fussey, Ph.D. Reg. No. 39,458

Agent for Applicants

WILLIAMS, MORGAN & AMERSON, P.C. 10333 Richmond, Suite 1100 Houston, Texas, 77042 (713) 934-4079

Date: December 9, 2002

مس م



							ragerori	
Form P	PTO-144	9 (modified)		Atty. Docket No. 4001.002282		Serial No 09/351,86		
002		d Publications for ON DISCLOSURE S	Applicant Philip E. Thorpe and Sophia Ran Filing Date: July 12, 1999 Patent Documents See Page O9/351,862 Group: 1617 Other Art See Page 1			DEC 1 9		
ADW RELL	(Use s	everal sheets if necessa	ary)	Filing Date: July 12, 1999		Group: 1617	1600	
U.	U.S. Patent Documents See Page			eign Patent Documents See Page		Othe	er Art Repage 1	
			U.S. Pate	ent Documer	nts			
Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.	
				1 15				
	, <u>-</u>	F	oreign Pa	tent Docum	ents	1 .		
Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No	
	<u> </u>							
(Other A	Art (Includir	ng Author,	Title, Date	Pertiner	t Page	s, Etc.)	
Exam. Init.	Ref. Des.		Citation					
	C67		, "Monoclonal Antibody Against Phosphatidylserine Inhibits <i>In Vitro</i> Human mone Production and Invasion," <i>Biology Reproduction</i> , 56:50-58, 1997.					
	C68			ntiphosphatidylserine Antibody Reacts Against Cytoskeletonan Umbilical Cord Endothelial Cells," <i>AJRI</i> , 33:97-107, 1995.				
	C69 Obringer et al., "Antiphospholipid Antibody Binding to Bilayer-Coated Glass Microspholipid Methods, 185:81-93, 1995.							
	C70		•	Antibody to Phos , 1194(1):155-165,	•	e Inhibits	Na+/K(+)-ATPase	

ŀ

$\mathbf{E}\mathbf{X}\mathbf{A}$	MI	NE	R:
----------------------------------	----	----	----

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.